FindTrial
Sign In

De-escalation

RADIATION5 trials

Sponsors

University of Bologna, Region Skane, Royal North Shore Hospital, UNICANCER, Faculty of Medicine Ramathibodi Hospital, Mahidol University

Conditions

Abdominal InfectionBreast CancerCritically ill patients Circulatory shock Fluid de-escalation VExUS Fluid de-escalation Fluid removal ToleranceHPV Positive Oropharyngeal Squamous Cell CarcinomaInvasive Candidiases

Phase 3

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
RecruitingNCT07237256
UNICANCERBreast Cancer
Start: 2025-12-18End: 2037-12-31Target: 3902Updated: 2026-05-26

Unknown Phase

A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis
TerminatedNCT03090334
University of BolognaAbdominal Infection, Invasive Candidiases
Start: 2017-03-01End: 2019-06-10Updated: 2024-08-28
The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.
RecruitingNCT05634889
Region SkaneBreast Cancer
Start: 2023-03-17End: 2033-12-31Target: 1350Updated: 2026-05-11
De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)
RecruitingNCT06307015
Royal North Shore HospitalHPV Positive Oropharyngeal Squamous Cell Carcinoma
Start: 2025-04-01End: 2031-12-31Target: 25Updated: 2025-07-30
The Venous Excess Ultrasound (VExUS) grading to predict tolerance to fluid de-escalation in critically ill patients
TCTR20240409004
Faculty of Medicine Ramathibodi Hospital, Mahidol UniversityCritically ill patients Circulatory shock Fluid de-escalation VExUS Fluid de-escalation Fluid removal Tolerance
Start: 2024-04-10Target: 65Updated: 2026-08-03

Related Papers

NoLEEta: No chemotherapy in intermediate-risk HR+ HER2− early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.
Journal of Clinical Oncology2026-05-28
Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial
BMJ Open2023-09-0117 citations